ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Exploration and application of nanotechnology in precision transarterial chemoembolization for hepatocellular carcinoma].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Transarterial chemoembolization (TACE) is a first-line therapy for intermediate-to-advanced- stage hepatocellular carcinoma, but its clinical efficacy is often limited by incomplete embolization, systemic toxicity of chemotherapeutic drugs, and tumor recurrence and metastasis caused by the postoperative microenvironment. The emergence of nanotechnology provides a novel solution to overcome these bottlenecks. This article aims to review new strategies and clinical translations of nanoparticles as intelligent carriers in enhancing the TACE efficacy. Furthermore, it focuses on the latest advances of nanotechnology in achieving precise embolization, targeted drug delivery, multimodal imaging guidance, and others. This article further analyzes the new concept of the synergistic therapeutic approach of loading anti-angiogenic drugs or active ingredients from traditional Chinese medicine onto nanocarriers to synergistically enhance the anti-recurrence effect of TACE, and lists relevant nanomedicine cases that have entered clinical trials. Although nanotechnology still faces challenges, such as biosafety profile, large-scale production, and personalized application in the clinical translation of TACE, the deep integration of materials science, interventional medicine, and biotechnology to build an "integrated diagnosis and treatment" intelligent nanoplatform will surely propel TACE from empirical treatment to a new era of precision medicine, opening up new avenues for improving the prognosis of patients with intermediate and advanced stage HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.